The US Supreme Court will soon decide the fate of a $6 billion settlement between members of the Sackler family and their bankrupt drugmaker Purdue Pharma LP, which profited from the sale of the painkiller OxyContin. The high-stakes legal battle comes as the Court reviews a Biden administration challenge aiming to dismantle the agreement.
This legal settlement, central to Purdue Pharma’s restructuring plan, involves certain Sackler family members, who own the company but are not under bankruptcy themselves. According to the agreement, the Sacklers would provide funding intended for compensating opioid victims and various government entities. In return, they would gain immunity from all pending and future civil lawsuits related to Purdue’s actions and OxyContin sales.
The pivotal question before the Supreme Court is whether such a settlement, effectively granting wide-ranging civil immunity to individuals not under bankruptcy protection, is permissible within the scope of US bankruptcy law. The Biden administration argues that this settlement structure circumvents the traditional legal process for holding individuals accountable for their actions.
The outcome of this case could set a significant precedent for future bankruptcy settlements involving non-debtors and will be closely watched by legal professionals and corporations alike. For more detailed information, see the full article on Bloomberg Law.